aflibercept 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
vascular endothelial growth factor (VEGF) receptors 4916 862111-32-8

Description:

MoleculeDescription

Synonyms:

  • aflibercept
  • eylea
  • AVE0005
  • ziv-aflibercept
  • zaltrap
  • VEGF Trap
has antiangiogenic activity; consists of the second and third Ig domains of VEGFR1 and VEGFR2, respectively, fusion to the Fc region of IgG1; putative antineoplastic agent that binds all VEGF-A isoforms; possible medicine for eye disorders
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
20 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
March 25, 2020 PMDA Bayer Yakuhin, Ltd
Nov. 22, 2012 EMA Bayer AG
Nov. 18, 2011 FDA REGENERON PHARMACEUTICALS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Endophthalmitis 1293.34 29.82 251 10227 4434 90613535
Visual acuity reduced 1053.42 29.82 286 10192 23124 90594845
Blindness 851.40 29.82 249 10229 26319 90591650
Eye inflammation 685.24 29.82 163 10315 7688 90610281
Vitritis 605.28 29.82 112 10366 1502 90616467
Visual impairment 540.86 29.82 276 10202 132089 90485880
Blindness unilateral 523.98 29.82 131 10347 7605 90610364
Non-infectious endophthalmitis 522.80 29.82 78 10400 228 90617741
Vitreous floaters 447.81 29.82 115 10363 7434 90610535
Uveitis 426.23 29.82 130 10348 15773 90602196
Blindness transient 394.54 29.82 94 10384 4449 90613520
Eye pain 366.53 29.82 151 10327 44017 90573952
Subretinal fluid 349.67 29.82 62 10416 642 90617327
Retinal haemorrhage 337.87 29.82 87 10391 5677 90612292
Anterior chamber cell 327.20 29.82 59 10419 677 90617292
Vitreous opacities 311.98 29.82 53 10425 417 90617552
Intraocular pressure increased 306.00 29.82 84 10394 7009 90610960
Iridocyclitis 237.84 29.82 60 10418 3601 90614368
Detachment of retinal pigment epithelium 227.86 29.82 41 10437 464 90617505
Retinal oedema 220.31 29.82 45 10433 1031 90616938
Keratic precipitates 211.46 29.82 36 10442 287 90617682
Retinal vasculitis 209.75 29.82 46 10432 1495 90616474
Vision blurred 204.17 29.82 138 10340 110155 90507814
Death 199.80 29.82 254 10224 456297 90161672
Anterior chamber inflammation 188.85 29.82 34 10444 386 90617583
Retinal artery occlusion 181.70 29.82 44 10434 2227 90615742
Vitreous disorder 179.64 29.82 28 10450 118 90617851
Vitreous haemorrhage 175.35 29.82 44 10434 2582 90615387
Vitrectomy 172.43 29.82 29 10449 213 90617756
Intra-ocular injection complication 170.82 29.82 24 10454 38 90617931
Vitreal cells 154.19 29.82 24 10454 100 90617869
Hypopyon 145.28 29.82 31 10447 883 90617086
Macular oedema 143.74 29.82 43 10435 4866 90613103
Anterior chamber flare 139.25 29.82 22 10456 103 90617866
Iritis 133.13 29.82 38 10440 3648 90614321
Retinal occlusive vasculitis 118.88 29.82 21 10457 212 90617757
Bacterial endophthalmitis 107.54 29.82 19 10459 192 90617777
Neovascular age-related macular degeneration 105.89 29.82 21 10457 412 90617557
Eye haemorrhage 105.83 29.82 41 10437 10139 90607830
Proteinuria 95.96 29.82 49 10429 23242 90594727
Choroidal neovascularisation 95.08 29.82 19 10459 388 90617581
Vitreous haze 89.81 29.82 14 10464 59 90617910
Age-related macular degeneration 89.49 29.82 20 10458 709 90617260
Neutropenia 83.86 29.82 116 10362 224788 90393181
Retinal pigment epithelial tear 83.82 29.82 16 10462 255 90617714
Product dose omission issue 82.32 29.82 132 10346 291555 90326414
Hypertensive crisis 80.85 29.82 40 10438 17744 90600225
Inadequate aseptic technique in use of product 78.53 29.82 12 10466 43 90617926
Visual acuity reduced transiently 73.95 29.82 14 10464 213 90617756
Retinal detachment 72.77 29.82 28 10450 6794 90611175
Ocular hyperaemia 71.42 29.82 46 10432 33752 90584217
Macular hole 68.23 29.82 17 10461 968 90617001
Polypoidal choroidal vasculopathy 67.62 29.82 11 10467 64 90617905
Hypertension 67.22 29.82 157 10321 457375 90160594
Corneal oedema 65.97 29.82 19 10459 1882 90616087
Disease progression 64.76 29.82 85 10393 156530 90461439
Retinal vein occlusion 64.61 29.82 20 10458 2536 90615433
Metamorphopsia 61.63 29.82 17 10461 1440 90616529
Hypotony of eye 61.48 29.82 12 10466 216 90617753
Visual field defect 61.03 29.82 25 10453 7141 90610828
Retinal vascular occlusion 59.09 29.82 13 10465 428 90617541
Eye irritation 56.82 29.82 40 10438 33938 90584031
Retinal thickening 53.43 29.82 12 10466 435 90617534
Retinal disorder 52.69 29.82 16 10462 1903 90616066
Ocular hypertension 50.41 29.82 15 10463 1665 90616304
Dry age-related macular degeneration 48.26 29.82 10 10468 246 90617723
Retinal exudates 48.15 29.82 12 10466 684 90617285
Cataract 48.00 29.82 50 10428 72042 90545927
Off label use 43.92 29.82 246 10232 1102006 89515963
Retinal ischaemia 42.42 29.82 10 10468 450 90617519
Retinal vascular disorder 42.21 29.82 9 10469 255 90617714
Chorioretinitis 41.22 29.82 11 10467 822 90617147
Abdominal discomfort 40.81 29.82 4 10474 477324 90140645
Retinal depigmentation 40.80 29.82 9 10469 300 90617669
Product use issue 40.71 29.82 106 10372 329813 90288156
Ocular discomfort 40.28 29.82 18 10460 6352 90611617
Eye oedema 39.93 29.82 13 10465 1939 90616030
Intentional dose omission 39.53 29.82 25 10453 17758 90600211
Retinal tear 39.01 29.82 12 10466 1490 90616479
Corneal deposits 38.95 29.82 9 10469 371 90617598
Amaurosis fugax 38.91 29.82 10 10468 645 90617324
Intraocular lens implant 38.69 29.82 9 10469 382 90617587
Vitreous detachment 37.41 29.82 13 10465 2365 90615604
Arthralgia 37.24 29.82 22 10456 778500 89839469
Glaucoma 36.01 29.82 25 10453 20730 90597239
Macular thickening 35.55 29.82 5 10473 8 90617961
Conjunctival disorder 35.25 29.82 8 10470 304 90617665
Drug intolerance 35.17 29.82 5 10473 447586 90170383
Anterior chamber disorder 34.89 29.82 7 10471 146 90617823
Retinal perivascular sheathing 34.69 29.82 6 10472 53 90617916
Swelling 34.57 29.82 4 10474 419054 90198915
Weight increased 34.45 29.82 4 10474 417923 90200046
Infusion related reaction 34.32 29.82 4 10474 416776 90201193
Syringe issue 34.21 29.82 14 10464 3988 90613981
Subretinal hyperreflective exudation 33.93 29.82 5 10473 13 90617956
Retinal degeneration 33.70 29.82 10 10468 1099 90616870
Eye discharge 32.92 29.82 17 10461 8241 90609728
Vena cava thrombosis 32.77 29.82 12 10466 2540 90615429
Multiple use of single-use product 32.72 29.82 11 10467 1812 90616157
Deposit eye 32.49 29.82 5 10473 19 90617950
Pain 32.10 29.82 41 10437 996300 89621669
Peripheral swelling 31.57 29.82 5 10473 413101 90204868
Stomatitis haemorrhagic 31.23 29.82 6 10472 99 90617870
Multiple-drug resistance 30.98 29.82 16 10462 7760 90610209
Corneal striae 30.90 29.82 5 10473 28 90617941
Ocular vasculitis 30.64 29.82 6 10472 110 90617859
Toxic anterior segment syndrome 30.46 29.82 11 10467 2239 90615730

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Visual acuity reduced 1097.21 27.36 334 11160 17216 42592625
Endophthalmitis 725.19 27.36 180 11314 4253 42605588
Retinal haemorrhage 465.39 27.36 134 11360 5636 42604205
Eye inflammation 448.41 27.36 115 11379 3103 42606738
Non-infectious endophthalmitis 398.11 27.36 68 11426 199 42609642
Blindness 387.88 27.36 155 11339 17823 42592018
Vitritis 380.24 27.36 84 11410 1165 42608676
Subretinal fluid 369.83 27.36 75 11419 668 42609173
Blindness transient 341.72 27.36 90 11404 2699 42607142
Intraocular pressure increased 323.91 27.36 104 11390 6329 42603512
Blindness unilateral 320.79 27.36 99 11395 5289 42604552
Vitreous opacities 315.28 27.36 61 11433 415 42609426
Visual impairment 312.31 27.36 175 11319 42938 42566903
Polypoidal choroidal vasculopathy 255.75 27.36 44 11450 136 42609705
Vitreous floaters 248.73 27.36 77 11417 4153 42605688
Detachment of retinal pigment epithelium 236.12 27.36 50 11444 560 42609281
Eye pain 234.93 27.36 107 11387 16923 42592918
Retinal oedema 234.32 27.36 54 11440 914 42608927
Uveitis 203.60 27.36 81 11413 9177 42600664
Intra-ocular injection complication 185.93 27.36 28 11466 22 42609819
Vitreous haemorrhage 174.19 27.36 53 11441 2694 42607147
Anterior chamber cell 173.37 27.36 37 11457 431 42609410
Anterior chamber inflammation 161.43 27.36 34 11460 370 42609471
Vision blurred 155.13 27.36 123 11371 53576 42556265
Age-related macular degeneration 142.89 27.36 30 11464 321 42609520
Proteinuria 138.81 27.36 83 11411 22900 42586941
Retinal pigment epithelial tear 138.59 27.36 29 11465 305 42609536
Macular hole 137.57 27.36 29 11465 317 42609524
Macular oedema 136.81 27.36 47 11447 3522 42606319
Vitrectomy 135.90 27.36 25 11469 124 42609717
Choroidal neovascularisation 130.63 27.36 27 11467 266 42609575
Vitreous disorder 120.08 27.36 23 11471 147 42609694
Retinal vasculitis 118.79 27.36 29 11465 634 42609207
Eye haemorrhage 105.26 27.36 42 11452 4788 42605053
Hypopyon 104.04 27.36 25 11469 510 42609331
Dry age-related macular degeneration 102.66 27.36 19 11475 98 42609743
Retinal artery occlusion 100.03 27.36 33 11461 2182 42607659
Iritis 98.69 27.36 31 11463 1751 42608090
Hypertension 96.08 27.36 166 11328 167038 42442803
Death 95.93 27.36 311 11183 470874 42138967
Retinal detachment 93.08 27.36 42 11452 6483 42603358
Keratic precipitates 89.04 27.36 19 11475 221 42609620
Corneal oedema 86.02 27.36 27 11467 1521 42608320
Vitreal cells 85.63 27.36 15 11479 53 42609788
Colitis microscopic 81.56 27.36 31 11463 3102 42606739
Disease progression 80.35 27.36 141 11353 143515 42466326
Retinal occlusive vasculitis 77.59 27.36 14 11480 61 42609780
Proteus infection 76.22 27.36 24 11470 1366 42608475
Visual acuity reduced transiently 75.70 27.36 15 11479 117 42609724
Diarrhoea 72.78 27.36 280 11214 460569 42149272
Anterior chamber flare 67.88 27.36 13 11481 83 42609758
Neovascular age-related macular degeneration 66.33 27.36 15 11479 232 42609609
Bacterial endophthalmitis 64.25 27.36 13 11481 114 42609727
Ocular hypertension 63.81 27.36 20 11474 1121 42608720
Neutropenia 62.23 27.36 154 11340 199277 42410564
Retinal vein occlusion 60.35 27.36 22 11472 1959 42607882
Induration 60.18 27.36 19 11475 1091 42608750
Prothrombin level decreased 58.94 27.36 19 11475 1167 42608674
Ocular hyperaemia 55.77 27.36 41 11453 15922 42593919
Retinal degeneration 54.95 27.36 16 11478 697 42609144
Retinal thickening 53.96 27.36 14 11480 394 42609447
Drug interaction 53.86 27.36 5 11489 266994 42342847
Product dose omission issue 53.27 27.36 124 11370 154241 42455600
Clostridial infection 52.29 27.36 24 11470 3850 42605991
Serous retinal detachment 50.52 27.36 16 11478 928 42608913
Necrotising fasciitis 48.63 27.36 24 11470 4522 42605319
Ocular vasculitis 44.88 27.36 8 11486 32 42609809
Retinal ischaemia 42.03 27.36 12 11482 487 42609354
Ocular discomfort 41.45 27.36 19 11475 3038 42606803
Iridocyclitis 40.56 27.36 17 11477 2194 42607647
Macular thickening 40.35 27.36 7 11487 23 42609818
Stomatitis 39.90 27.36 58 11436 50271 42559570
Metamorphopsia 39.28 27.36 12 11482 617 42609224
Macular degeneration 38.29 27.36 17 11477 2524 42607317
Neutrophilia 36.19 27.36 21 11473 5471 42604370
Rectal tenesmus 35.90 27.36 13 11481 1135 42608706
Retinal vascular occlusion 35.90 27.36 9 11485 220 42609621
Retinal scar 35.89 27.36 10 11484 371 42609470
Retinal depigmentation 33.77 27.36 7 11487 70 42609771
Vitreous fibrin 33.75 27.36 5 11489 3 42609838
Ocular ischaemic syndrome 33.47 27.36 6 11488 25 42609816
Cardiomyopathy acute 33.33 27.36 7 11487 75 42609766
Visual field defect 32.85 27.36 19 11475 4919 42604922
Skin toxicity 32.77 27.36 21 11473 6528 42603313
Adenocarcinoma metastatic 32.76 27.36 7 11487 82 42609759
Stoma site haemorrhage 32.50 27.36 12 11482 1107 42608734
Intraocular pressure decreased 32.16 27.36 7 11487 90 42609751
Diaphragmatic operation 32.09 27.36 6 11488 33 42609808
Intestinal perforation 31.53 27.36 25 11469 10849 42598992
Retinal vascular disorder 31.37 27.36 8 11486 210 42609631
Eye oedema 30.77 27.36 11 11483 926 42608915
Multiple use of single-use product 30.35 27.36 9 11485 418 42609423
Injury associated with device 29.92 27.36 12 11482 1385 42608456
Vitreous detachment 29.90 27.36 11 11483 1005 42608836
Vitreous haze 29.22 27.36 6 11488 57 42609784
Blood lactic acid increased 28.87 27.36 21 11473 8018 42601823
Scleritis 28.76 27.36 10 11484 776 42609065
Klebsiella infection 28.54 27.36 24 11470 11308 42598533
Cataract 28.32 27.36 38 11456 30566 42579275
Optical coherence tomography abnormal 27.81 27.36 7 11487 174 42609667
Somnolence 27.49 27.36 3 11491 141102 42468739

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Visual acuity reduced 1683.12 25.26 476 17485 31697 110539641
Endophthalmitis 1318.62 25.26 298 17663 7889 110563449
Eye inflammation 871.76 25.26 218 17743 8953 110562385
Vitritis 752.44 25.26 154 17807 2499 110568839
Retinal haemorrhage 674.32 25.26 179 17782 9322 110562016
Subretinal fluid 625.14 25.26 118 17843 1226 110570112
Vitreous opacities 587.32 25.26 105 17856 784 110570554
Blindness 579.48 25.26 219 17742 36140 110535198
Vitreous floaters 489.54 25.26 138 17823 8996 110562342
Uveitis 481.53 25.26 167 17794 21543 110549795
Non-infectious endophthalmitis 466.23 25.26 79 17882 412 110570926
Eye pain 465.68 25.26 205 17756 49894 110521444
Intraocular pressure increased 448.33 25.26 134 17827 10742 110560596
Blindness unilateral 435.79 25.26 128 17833 9658 110561680
Blindness transient 412.01 25.26 110 17851 5846 110565492
Anterior chamber cell 394.38 25.26 79 17882 1142 110570196
Visual impairment 387.71 25.26 252 17709 134176 110437162
Detachment of retinal pigment epithelium 366.74 25.26 72 17889 933 110570405
Retinal oedema 360.38 25.26 77 17884 1550 110569788
Anterior chamber inflammation 328.82 25.26 63 17898 712 110570626
Polypoidal choroidal vasculopathy 327.99 25.26 53 17908 194 110571144
Intra-ocular injection complication 297.72 25.26 43 17918 53 110571285
Retinal vasculitis 294.21 25.26 68 17893 1981 110569357
Vitreous haemorrhage 285.14 25.26 78 17883 4542 110566796
Vision blurred 261.78 25.26 195 17766 128827 110442511
Vitrectomy 259.22 25.26 44 17917 232 110571106
Vitreal cells 240.86 25.26 39 17922 145 110571193
Proteinuria 233.84 25.26 119 17842 39899 110531439
Death 231.25 25.26 409 17552 698460 109872878
Vitreous disorder 230.88 25.26 42 17919 349 110570989
Retinal artery occlusion 226.71 25.26 64 17897 4185 110567153
Keratic precipitates 222.27 25.26 43 17918 513 110570825
Macular oedema 220.02 25.26 70 17891 6896 110564442
Hypopyon 213.20 25.26 49 17912 1391 110569947
Age-related macular degeneration 198.28 25.26 43 17918 930 110570408
Iridocyclitis 190.20 25.26 59 17902 5349 110565989
Retinal pigment epithelial tear 189.62 25.26 37 17924 463 110570875
Anterior chamber flare 185.88 25.26 32 17929 186 110571152
Macular hole 179.25 25.26 40 17921 991 110570347
Choroidal neovascularisation 173.54 25.26 35 17926 524 110570814
Neutropenia 163.72 25.26 249 17712 374371 110196967
Hypertension 162.48 25.26 294 17667 509790 110061548
Disease progression 160.84 25.26 198 17763 243836 110327502
Iritis 156.26 25.26 49 17912 4603 110566735
Eye haemorrhage 135.11 25.26 56 17905 11718 110559620
Retinal occlusive vasculitis 128.56 25.26 24 17937 233 110571105
Corneal oedema 125.98 25.26 38 17923 3135 110568203
Diarrhoea 122.73 25.26 434 17527 1139071 109432267
Retinal detachment 121.34 25.26 51 17910 11049 110560289
Dry age-related macular degeneration 118.22 25.26 23 17938 283 110571055
Vitreous haze 104.35 25.26 18 17943 106 110571232
Visual acuity reduced transiently 99.12 25.26 20 17941 300 110571038
Retinal vein occlusion 93.33 25.26 32 17929 3975 110567363
Neovascular age-related macular degeneration 92.40 25.26 21 17940 566 110570772
Retinal vascular occlusion 90.99 25.26 21 17940 607 110570731
Ocular hyperaemia 90.03 25.26 64 17897 39222 110532116
Colitis microscopic 87.53 25.26 43 17918 13351 110557987
Multiple use of single-use product 85.18 25.26 23 17938 1273 110570065
Metamorphopsia 79.92 25.26 23 17938 1610 110569728
Bacterial endophthalmitis 74.67 25.26 16 17945 326 110571012
Retinal vascular disorder 71.82 25.26 16 17945 393 110570945
Ocular hypertension 71.12 25.26 23 17938 2385 110568953
Visual field defect 70.83 25.26 34 17927 10038 110561300
Inadequate aseptic technique in use of product 70.42 25.26 13 17948 118 110571220
Proteus infection 67.49 25.26 23 17938 2805 110568533
Retinal ischaemia 66.79 25.26 18 17943 989 110570349
Retinal depigmentation 62.53 25.26 14 17947 352 110570986
Hypertensive crisis 61.20 25.26 42 17919 24330 110547008
Retinal thickening 59.25 25.26 13 17948 297 110571041
Retinal exudates 58.03 25.26 17 17944 1267 110570071
Prothrombin level decreased 56.37 25.26 18 17943 1792 110569546
Weight increased 55.90 25.26 3 17958 419641 110151697
Epistaxis 55.83 25.26 86 17875 130286 110441052
Macular thickening 55.46 25.26 9 17952 34 110571304
Retinal degeneration 53.67 25.26 17 17944 1649 110569689
Drug interaction 52.58 25.26 9 17952 500174 110071164
Off label use 52.13 25.26 418 17543 1499767 109071571
Ocular discomfort 51.63 25.26 26 17935 8507 110562831
Retinal disorder 51.61 25.26 18 17943 2352 110568986
Induration 51.47 25.26 18 17943 2371 110568967
Ocular vasculitis 51.25 25.26 10 17951 125 110571213
Cerebral infarction 51.15 25.26 52 17909 51786 110519552
Arthralgia 50.86 25.26 32 17929 779600 109791738
Clostridial infection 49.62 25.26 23 17938 6279 110565059
Serous retinal detachment 49.50 25.26 16 17945 1656 110569682
Dysphonia 48.92 25.26 61 17900 75868 110495470
Pain 47.68 25.26 51 17910 954904 109616434
Eye irritation 47.33 25.26 41 17920 33411 110537927
Nasopharyngitis 46.40 25.26 5 17956 394356 110176982
Necrotising fasciitis 45.55 25.26 23 17938 7568 110563770
Mucosal inflammation 44.82 25.26 66 17895 96075 110475263
No adverse event 43.90 25.26 57 17904 73782 110497556
Abdominal discomfort 43.86 25.26 6 17955 393852 110177486
Retinal scar 43.55 25.26 11 17950 468 110570870
Proctalgia 43.52 25.26 27 17934 13195 110558143
Swelling 42.46 25.26 4 17957 351037 110220301
Pseudoendophthalmitis 42.46 25.26 8 17953 82 110571256
Nephrotic syndrome 42.40 25.26 27 17934 13804 110557534
Vitreous detachment 42.20 25.26 16 17945 2649 110568689
Infusion related reaction 41.99 25.26 6 17955 381156 110190182
Toxic anterior segment syndrome 41.56 25.26 17 17944 3437 110567901
Drug intolerance 41.23 25.26 8 17953 406504 110164834
Retinal perivascular sheathing 40.50 25.26 8 17953 107 110571231
Subretinal hyperreflective exudation 39.77 25.26 6 17955 12 110571326
Retinal tear 39.18 25.26 14 17947 1963 110569375
Hypotony of eye 38.73 25.26 10 17951 465 110570873
Palmar-plantar erythrodysaesthesia syndrome 38.39 25.26 40 17921 40985 110530353
Optical coherence tomography abnormal 37.77 25.26 8 17953 154 110571184
Cataract 37.68 25.26 55 17906 79430 110491908
Rash 37.54 25.26 47 17914 820917 109750421
Neuropathy peripheral 37.44 25.26 87 17874 179190 110392148
Insomnia 36.77 25.26 7 17954 360583 110210755
Corneal deposits 36.48 25.26 10 17951 586 110570752
Haemorrhagic occlusive retinal vasculitis 35.34 25.26 7 17954 95 110571243
Diaphragmatic operation 35.13 25.26 6 17955 33 110571305
Ocular ischaemic syndrome 34.83 25.26 6 17955 35 110571303
Glaucoma 34.72 25.26 29 17932 22488 110548850
Macular fibrosis 34.55 25.26 10 17951 714 110570624
Intestinal perforation 34.44 25.26 28 17933 20916 110550422
Hiccups 34.26 25.26 23 17938 12846 110558492
Retinal neovascularisation 34.15 25.26 8 17953 247 110571091
Rectal tenesmus 33.73 25.26 13 17948 2249 110569089
Retinal cyst 32.33 25.26 7 17954 150 110571188
Pain in extremity 31.71 25.26 20 17941 487098 110084240
Stomatitis 31.46 25.26 106 17855 270136 110301202
Vena cava thrombosis 31.45 25.26 14 17947 3480 110567858
Klebsiella infection 31.33 25.26 26 17935 19983 110551355
Neutrophilia 31.26 25.26 20 17941 10309 110561029
Skin toxicity 31.23 25.26 21 17940 11762 110559576
Maternal exposure during pregnancy 30.56 25.26 3 17958 254880 110316458
Conjunctival hyperaemia 30.19 25.26 16 17945 5815 110565523
Pruritus 30.16 25.26 30 17931 581530 109989808
Diabetic retinal oedema 29.75 25.26 8 17953 436 110570902
Sinusitis 29.74 25.26 6 17955 296682 110274656
Choroidal detachment 29.59 25.26 9 17952 763 110570575
Stoma site haemorrhage 29.53 25.26 12 17949 2386 110568952
Pulmonary embolism 29.40 25.26 89 17872 214385 110356953
Urticaria 28.90 25.26 8 17953 318849 110252489
Lower respiratory tract infection 28.79 25.26 3 17958 243103 110328235
Posterior capsule opacification 28.66 25.26 7 17954 259 110571079
Hypoaesthesia 28.26 25.26 8 17953 314215 110257123
Chorioretinitis 27.96 25.26 10 17951 1405 110569933
Macular degeneration 27.56 25.26 25 17936 21634 110549704
Gastrointestinal toxicity 27.48 25.26 19 17942 11129 110560209
Suspected product quality issue 27.38 25.26 8 17953 591 110570747
Dyspnoea 27.04 25.26 91 17870 1106781 109464557
Colorectal cancer metastatic 26.83 25.26 10 17951 1579 110569759
Anterior chamber disorder 26.28 25.26 6 17955 165 110571173
Adenocarcinoma metastatic 25.83 25.26 7 17954 393 110570945
Cardiomyopathy acute 25.72 25.26 7 17954 399 110570939
Intraocular pressure decreased 25.62 25.26 6 17955 185 110571153
Scleritis 25.62 25.26 14 17947 5406 110565932
Vitreous adhesions 25.59 25.26 5 17956 63 110571275
Asthenia 25.39 25.26 195 17766 688804 109882534
Musculoskeletal stiffness 25.39 25.26 7 17954 279815 110291523
Choroidal haemorrhage 25.38 25.26 6 17955 193 110571145
Conjunctival disorder 25.29 25.26 7 17954 425 110570913

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XX44 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
ATC S01LA05 SENSORY ORGANS
OPHTHALMOLOGICALS
OCULAR VASCULAR DISORDER AGENTS
Antineovascularisation agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D006131 Growth Inhibitors
MeSH PA D006133 Growth Substances
MeSH PA D020533 Angiogenesis Inhibitors
FDA MoA N0000193542 Vascular Endothelial Growth Factor Inhibitors
FDA EPC N0000193543 Vascular Endothelial Growth Factor Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:66981 ophthalmology drug

Related Drugs by ATC class:

L01XX Other antineoplastic agents 33 drugs
adagrasibaltretamineamsacrineanagrelidearsenic trioxideasparaginasebelzutifancalaspargase pegolcelecoxibdarinaparsindenileukin diftitoxeflornithine show all 33 →
S01LA Antineovascularisation agents 7 drugs
anecortavebevacizumabbrolucizumabfaricimabpegaptanibranibizumabverteporfin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Central retinal vein occlusion with macular edema indication 232039004
Branch retinal vein occlusion with macular edema indication 232048009
Neovascular glaucoma indication 232086000 DOID:1687
Macular edema due to diabetes mellitus indication 312912001 DOID:9191
Metastasis from malignant tumor of colon indication 314998002
Exudative age-related macular degeneration indication 414173003 DOID:10873
Retinopathy of prematurity indication 415297005 DOID:13025
Myopic choroidal neovascularization indication 733124000
Uveitis contraindication 128473001 DOID:13141




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Vascular endothelial growth factor A Secreted INHIBITOR Kd 12.30 DRUG LABEL DRUG LABEL
Placenta growth factor Secreted INHIBITOR Kd 10.41 DRUG LABEL DRUG LABEL
Vascular endothelial growth factor B Secreted INHIBITOR Kd 11.72 DRUG LABEL DRUG LABEL

External reference:

IDSource
15C2VL427D UNII
D09574 KEGG_DRUG
4031234 VUID
N0000184016 NUI
4031234 VANDF
4031980 VANDF
C1134659 UMLSCUI
CHEBI:750062 CHEBI
CHEMBL1742982 ChEMBL_ID
DB08885 DRUGBANK_ID
8739 INN_ID
C533178 MESH_SUPPLEMENTAL_RECORD_UI
6786 IUPHAR_LIGAND_ID
1232150 RXNORM
186189 MMSL
192290 MMSL
28208 MMSL
28701 MMSL
d07888 MMSL
014044 NDDF
015046 NDDF
703840003 SNOMEDCT_US
714627007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZALTRAP HUMAN PRESCRIPTION DRUG LABEL 1 0024-5840 SOLUTION, CONCENTRATE 100 mg INTRAVENOUS BLA 32 sections
ZALTRAP HUMAN PRESCRIPTION DRUG LABEL 1 0024-5840 SOLUTION, CONCENTRATE 100 mg INTRAVENOUS BLA 32 sections
ZALTRAP HUMAN PRESCRIPTION DRUG LABEL 1 0024-5841 SOLUTION, CONCENTRATE 200 mg INTRAVENOUS BLA 32 sections
ZALTRAP HUMAN PRESCRIPTION DRUG LABEL 1 0024-5841 SOLUTION, CONCENTRATE 200 mg INTRAVENOUS BLA 32 sections
PAVBLU HUMAN PRESCRIPTION DRUG LABEL 1 55513-056 INJECTION, SOLUTION 2 mg INTRAVITREAL BLA 30 sections
PAVBLU HUMAN PRESCRIPTION DRUG LABEL 1 55513-065 INJECTION, SOLUTION 2 mg INTRAVITREAL BLA 30 sections
EYLEA HUMAN PRESCRIPTION DRUG LABEL 1 61755-005 INJECTION, SOLUTION 40 mg INTRAVITREAL BLA 31 sections
EYLEA HD HUMAN PRESCRIPTION DRUG LABEL 1 61755-050 INJECTION, SOLUTION 8 mg INTRAVITREAL BLA 31 sections
EYLEA HD HUMAN PRESCRIPTION DRUG LABEL 1 61755-051 INJECTION, SOLUTION 8 mg INTRAVITREAL BLA 31 sections
EYDENZELTboav HUMAN PRESCRIPTION DRUG LABEL 1 72606-026 INJECTION 2 mg INTRAVITREAL BLA 29 sections
AHZANTIVE HUMAN PRESCRIPTION DRUG LABEL 1 85006-2908 INJECTION, SOLUTION 40 mg INTRAVITREAL BLA 16 sections
AHZANTIVE HUMAN PRESCRIPTION DRUG LABEL 1 85006-2908 INJECTION, SOLUTION 2 mg INTRAVITREAL BLA 16 sections